87 related articles for article (PubMed ID: 34094664)
1. Exosomal long noncoding RNA AGAP2-AS1 regulates trastuzumab resistance via inducing autophagy in breast cancer.
Qian X; Qu H; Zhang F; Peng S; Dou D; Yang Y; Ding Y; Xie M; Dong H; Liao Y; Han M
Am J Cancer Res; 2021; 11(5):1962-1981. PubMed ID: 34094664
[TBL] [Abstract][Full Text] [Related]
2. M6A RNA methylation-mediated dysregulation of AGAP2-AS1 promotes trastuzumab resistance of breast cancer.
Cai Y; Zheng H; Xu D; Xie J; Wang W; Liu Z; Zheng Z
Pharmacology; 2024 May; ():. PubMed ID: 38744264
[TBL] [Abstract][Full Text] [Related]
3. Statement of Retraction: Knockdown of long non-coding RNA AGAP2-AS1 suppresses the proliferation and metastasis of glioma by targeting microRNA-497-5p.
Bioengineered; 2024 Dec; 15(1):2302648. PubMed ID: 38239060
[No Abstract] [Full Text] [Related]
4. Retraction Note: miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2024 Jun; ():. PubMed ID: 38839893
[No Abstract] [Full Text] [Related]
5. Correction to: Activation of LncRNA TINCR by H3K27 acetylation promotes Trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast Cancer.
Dong H; Hu J; Zou K; Ye M; Chen Y; Wu C; Chen X; Han M
Mol Cancer; 2021 Jun; 20(1):87. PubMed ID: 34116680
[No Abstract] [Full Text] [Related]
6. A novel long non-coding RNA AC073352.1 promotes metastasis and angiogenesis via interacting with YBX1 in breast cancer.
Kong X; Li J; Li Y; Duan W; Qi Q; Wang T; Yang Q; Du L; Mao H; Wang C
Cell Death Dis; 2021 Jul; 12(7):670. PubMed ID: 34218256
[TBL] [Abstract][Full Text] [Related]
7. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Chen YP; Liu X; Zhou Q; Yang KY; Jin F; Zhu XD; Shi M; Hu GQ; Hu WH; Sun Y; Wu HF; Wu H; Lin Q; Wang H; Tian Y; Zhang N; Wang XC; Shen LF; Liu ZZ; Huang J; Luo XL; Li L; Zang J; Mei Q; Zheng BM; Yue D; Xu J; Wu SG; Shi YX; Mao YP; Chen L; Li WF; Zhou GQ; Sun R; Guo R; Zhang Y; Xu C; Lv JW; Guo Y; Feng HX; Tang LL; Xie FY; Sun Y; Ma J
Lancet; 2021 Jul; 398(10297):303-313. PubMed ID: 34111416
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
[TBL] [Abstract][Full Text] [Related]
9. Identification and Roles of miR-29b-1-3p and miR29a-3p-Regulated and Non-Regulated lncRNAs in Endocrine-Sensitive and Resistant Breast Cancer Cells.
Muluhngwi P; Klinge CM
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298743
[TBL] [Abstract][Full Text] [Related]
10. Tumour-derived exosomal lncRNA-SOX2OT promotes bone metastasis of non-small cell lung cancer by targeting the miRNA-194-5p/RAC1 signalling axis in osteoclasts.
Ni J; Zhang X; Li J; Zheng Z; Zhang J; Zhao W; Liu L
Cell Death Dis; 2021 Jul; 12(7):662. PubMed ID: 34215717
[TBL] [Abstract][Full Text] [Related]
11. Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Pernas S; Tolaney SM
JCO Oncol Pract; 2021 Jun; 17(6):320-330. PubMed ID: 34111378
[TBL] [Abstract][Full Text] [Related]
12. Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Jhaveri KL; Wang XV; Makker V; Luoh SW; Mitchell EP; Zwiebel JA; Sharon E; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
Ann Oncol; 2021 Aug; 32(8):1068. PubMed ID: 34099371
[No Abstract] [Full Text] [Related]
13. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
[TBL] [Abstract][Full Text] [Related]
14. Expanding the horizon of EV-RNAs: LncRNAs in EVs as biomarkers for disease pathways.
Spanos M; Gokulnath P; Chatterjee E; Li G; Varrias D; Das S
Extracell Vesicle; 2023 Dec; 2():. PubMed ID: 38188000
[TBL] [Abstract][Full Text] [Related]
15. The Role of the Tumor Microenvironment in Triple-Positive Breast Cancer Progression and Therapeutic Resistance.
Pu Q; Gao H
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001753
[TBL] [Abstract][Full Text] [Related]
16. A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response.
Duan WW; Yang LT; Liu J; Dai ZY; Wang ZY; Zhang H; Zhang X; Liang XS; Luo P; Zhang J; Liu ZQ; Zhang N; Mo HY; Qu CR; Xia ZW; Cheng Q
CNS Neurosci Ther; 2024 Apr; 30(4):e14489. PubMed ID: 37850692
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNAs: controversial roles in drug resistance of solid tumors mediated by autophagy.
Saadh MJ; Almoyad MAA; Arellano MTC; Maaliw RR; Castillo-Acobo RY; Jalal SS; Gandla K; Obaid M; Abdulwahed AJ; Ibrahem AA; Sârbu I; Juyal A; Lakshmaiya N; Akhavan-Sigari R
Cancer Chemother Pharmacol; 2023 Dec; 92(6):439-453. PubMed ID: 37768333
[TBL] [Abstract][Full Text] [Related]
18. Deciphering the Functional Status of Breast Cancers through the Analysis of Their Extracellular Vesicles.
Murillo Carrasco AG; Otake AH; Macedo-da-Silva J; Feijoli Santiago V; Palmisano G; Andrade LNS; Chammas R
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629204
[TBL] [Abstract][Full Text] [Related]
19. Unveiling the functional paradigm of exosome-derived long non-coding RNAs (lncRNAs) in cancer: based on a narrative review and systematic review.
Wu W; He J
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15219-15247. PubMed ID: 37578522
[TBL] [Abstract][Full Text] [Related]
20. Autophagy and Breast Cancer: Connected in Growth, Progression, and Therapy.
Wu Q; Sharma D
Cells; 2023 Apr; 12(8):. PubMed ID: 37190065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
